169237-39-2

Basic information

• Product Name: 2-Thiazolidinethione, 3-[[1,2-dihydro-1-methyl-2-oxo-3-(phenylmethoxy)-4-pyridinyl]carbonyl]-
• CAS NO: 169237-39-2
• Molecular Formula: C17H16N2O3S2
• Molecular Weight: 360.458
• Mol File: 169237-39-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-Thiazolidinethione, 3-[[1,2-dihydro-1-methyl-2-oxo-3-(phenylmethoxy)-4-pyridinyl]carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolidinethione, 3-[[1,2-dihydro-1-methyl-2-oxo-3-(phenylmethoxy)-4-pyridinyl]carbonyl]-(169237-39-2)
• EPA Substance Registry System: 2-Thiazolidinethione, 3-[[1,2-dihydro-1-methyl-2-oxo-3-(phenylmethoxy)-4-pyridinyl]carbonyl]-(169237-39-2)

Safety Data

• Hazardous Substances Data: 169237-39-2(Hazardous Substances Data)

Upstream product

• 96-53-7 2-mercaptothiazoline 
• 169237-38-1 3-benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone 
• 500372-11-2 ethyl 3-hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylate 
• 21472-88-8 5-hydroxy-6-oxo-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester 
• 100-39-0 benzyl bromide 
• 130879-43-5 3-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid ethyl ester 
• 84719-32-4 3-Hydroxy-2(1H)-pyridinone 
• 134469-06-0 thiazolidine-2-thione 
• 1025989-29-0 benzyl 3-(benzyloxy)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate 
• 169237-37-0 4-carboxy-1-methyl-3-hydroxy-2(1H)-pyridinone 
• 19365-01-6 1-methyl-3-hydroxy-2(1H)-pyridinone 

Downstream Products

• 169237-40-5 C₄₈H₅₁N₇O₉ 
• 1027954-03-5 C₆₇H₇₄N₁₀O₁₂ 
• 186834-20-8 C₃₁H₃₂N₄O₆ 
• 848490-02-8 3-benzyloxy-1-methyl-2-oxo-1,2-dihydro-pyridine-4-carboxylic acid (3-amino-propyl)-amide 
• 593247-69-9 TREN-1-Me-3,2-HOPO-TAM₂, benzyl protected 
• 518046-69-0 1-Bn-6-Me-3,2-HOPO-thiazolide 
• 186834-11-7 3-benzyloxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone 
• 1092925-79-5 C₆₂H₆₁N₅O₉ 
• 1330063-50-7 ALG-001 
• 186834-29-7 {[2-(Bis-{2-[(3-benzyloxy-1-methyl-2-oxo-1,2-dihydro-pyridine-4-carbonyl)-amino]-ethyl}-amino)-ethyl]-carboxymethyl-amino}-acetic acid 
• 186834-25-3 C₅₁H₄₈N₆O₉ 
• 186834-26-4 C₆₆H₇₂N₁₀O₁₂ 
• 518046-70-3 TREN-Gly-1-Me-3,2-HOPO, benzyl protected 
• 460986-10-1 3,4,3-LI-(1,2-Me-3,2-HOPO)Bn 

Relevant articles and documents

RADIO-PHARMACEUTICAL COMPLEXES

The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a

Alpha-emitting complexes

The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

An efficient chelator for complexation of thorium-227

We present the synthesis and characterization of a highly efficient thorium chelator, derived from the octadentate hydroxypyridinone class of compounds. The chelator forms extremely stable complexes with fast formation rates in the presence of Th-227 (ambient temperature, 20?min). In addition, mouse biodistribution data are provided which indicate rapid hepatobiliary excretion route of the chelator which, together with low bone uptake, supports the stability of the complex in vivo. The carboxylic acid group may be readily activated for conjugation through the ?-amino groups of lysine residues in biomolecules such as antibodies. This chelator is a critical component of a new class of Targeted Thorium Conjugates (TTCs) currently under development in the field of oncology.